Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
CGTX
Stock Latest News
Ratings
Ram Selvaraju Reiterates Buy on Cognition Amid Clinical Progress and Regulatory Milestones, Keeps 12-Month Price Target Unchanged at $3
8d ago
CGTX
Premium
The Fly
Cognition Therapeutics reports Q1 EPS (5c), consensus (7c)
12d ago
CGTX
Premium
Ratings
Cognition Therapeutics: Buy Rating Backed by Zervimesine Pivotal Path and Risk‑Adjusted Upside Across Neurodegenerative Indications
2M ago
CGTX
Premium
Company Announcements
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress
2M ago
8K
CGTX
Premium
The Fly
Cognition Therapeutics’ zervimesine shows eficacy in dementia trial
2M ago
CGTX
Premium
Ratings
Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating
3M ago
CGTX
Premium
Company Announcements
Cognition Therapeutics Advances Zervimesine for DLB Psychosis
3M ago
8K
CGTX
Premium
The Fly
Cognition Therapeutics announces plans to advance development of zervimesine
3M ago
CGTX
Premium
The Fly
Cognition Therapeutics extends duration of EAP for zervimesine
3M ago
CGTX
Premium
Company Announcements
Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial
4M ago
8K
CGTX
Premium
The Fly
Cognition Therapeutics completes Type C meeting with FDA for zervimesine
4M ago
CGTX
Premium
The Fly
Cognition publishes Phase 2 results on Zervimesine
4M ago
CGTX
Premium
Company Announcements
Cognition Therapeutics Launches New $75M ATM Offering
5M ago
8K
CGTX
Premium
The Fly
Cognition Therapeutics files $300M mixed securities shelf
5M ago
CGTX
Premium
Ratings
Cognition Therapeutics’ Promising Advances in Dementia Treatment Justify Buy Rating
6M ago
CGTX
Premium
The Fly
Cognition reaches full enrollment in expanded access program for CT1812
6M ago
CGTX
Premium
The Fly
Cognition Therapeutics presents Phase 3 plan for zervimesine in Alzheimer’s
6M ago
CGTX
Premium
The Fly
Cognition Therapeutics price target raisd to $3 from $2 at B. Riley
6M ago
CGTX
Premium
The Fly
Cognition Therapeutics completes enrollment in Phase 2 study of Zervimesine
6M ago
CGTX
Premium
Ratings
Optimistic Buy Rating for Cognition Therapeutics Amid Promising Developments in Alzheimer’s and Dementia Treatment
6M ago
CGTX
Premium
Company Announcements
Cognition Therapeutics Advances Alzheimer’s Drug Development
6M ago
CGTX
Premium
The Fly
Cognition Therapeutics reports Q3 EPS (6c), consensus (9c)
6M ago
CGTX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
